Part the Cloud Translational Gene Targeting Challenge Grant

The Alzheimer's Association's Part the Cloud Translational Gene Targeting Challenge Grant aims to enhance early-phase human trials (Phase 1 and Phase 2) for therapies targeting the genetic causes of Alzheimer's disease and related dementias. With funding up to $2 million, it encourages innovative research internationally, with a focus on at least 10 clinical trials. This initiative represents a significant step towards advancing Alzheimer’s research and improving patient outcomes.

Alzheimer’s Association
The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.
Part the Cloud Translational (PTC) Gene Targeting Challenge Grant
Part the Cloud, a program through the Alzheimer's Association, announces a targeted challenge funding program focused on increasing early phase human trials (Phase 1 and Phase 2) of potential therapies tailored to the genetic underpinnings of Alzheimer’s disease and related dementias internationally.
Funding
Each grant is limited to $1,000,000 (direct and indirect costs) for Phase 1 studies and $2,000,000 for Phase 2 studies over two or three years. We anticipate funding a mix of phase 1 and phase 2 studies with available funding, minimum of 10 clinical trials. Indirect costs are only allowed for not for-profit institutions, and are capped at 10 percent (rent for laboratory/office space is expected to be covered by indirect costs paid to the institution). No indirect costs are allowed for profit organizations.